Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

day 35 after the injection of microplasmin or placebo, whether they had a vitrectomy or not. In patients who received the highest dose of microplasmin there was an improvement in vision (6.9 more letters read on a standard eye chart compared to a baseline reading prior to treatment); this compares with a 0.1 letter improvement for the placebo group.

Microplasmin in Stroke

In late September, the Company announced promising results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. The overall results of the study were presented by Dr. Vincent Thijs on September 27 at the World Stroke Congress in Vienna.

The MITI IV (Microplasmin In Treatment of Ischemic stroke - IntraVenous) trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety and preliminary efficacy of the intravenous administration of microplasmin in 40 patients, 4 to 12 hours after onset of acute ischemic stroke

The study found that microplasmin was generally well tolerated with no evidence of increased bleeding risk; there were no systemic bleeding events reported and there was no evidence of increased rate of bleeding in general, in those patients that had been treated with microplasmin compared to those treated with placebo.

In addition, the study provided some interesting preliminary efficacy results. Approximately 25% of patients treated with microplasmin had reperfusion (restoration of blood flow) within eight hours of being treated, this compares with 10% of placebo-treated patients. Moreover, of the patients who had more severe vascular blockages, 33% of patients treated with microplasmin achieved reperfusion compared with 14% of placebo-treated patients. Due to the small number of patients in this study, neither of these endpoints were statistically significant. However, the study also s
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Vital Imaging ™ has teamed ... San Diego for a joint study which aims to ... Resonance Imaging) with that of a supine Dynawell MRI ... of improved healthcare by combining cutting edge technology with ... valuable tool for evaluating pathological changes in the spine, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Clinovo's ... an 8-week training program starting on June 11th, 2013. ... clinical trial professionals reach the next step in their ... Offices in Palo Alto, and streamed online. , Taught ... award-winning papers, Clinovo's new “CDISC Standards: Theory and Application” ...
(Date:5/20/2013)... May 20, 2013 Today, at the American ... , James McGough , M.D., ... the Semel Institute for Neuroscience and Human Behavior and ... at the University of California Los Angeles (UCLA), and ... Adolescent Psychopharmacology and ADHD at UCLA, presented the results ...
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... eICU(R) Programs Close Critical Care Coverage Gap, WASHINGTON, ... at the forefront of the recent political campaigns is ... of the country. The government,recently took steps to alleviate ... Iowa residents -- a problem that is being exacerbated ...
... NVN) today announced financial results for the third,quarter and ... product developments and corporate milestones., ... corporate highlights:, o On October ... a corporate restructuring ...
... Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- China,Clean Energy Inc. (OTC ... announced that, as of November 10, 2008 it ... to resume biodiesel production at its,existing plant in ... prices, thus,allowing the Company to enjoy sufficient margins ...
Cached Biology Technology:USDA Awards $1.5 Million to Expand Access to High-Quality Critical Care in Rural Communities 2USDA Awards $1.5 Million to Expand Access to High-Quality Critical Care in Rural Communities 3Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 2Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 3Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 4Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 5Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 6Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 7China Clean Energy Resumes Biodiesel Production After Temporary Halt 2China Clean Energy Resumes Biodiesel Production After Temporary Halt 3
(Date:5/20/2013)... 2013) University of Minnesota Medical School researchers from ... with the University,s Brain Tumor Program, have developed a ... (MPNST) that allow them to discover new genes and ... research was published this week in the journal ... method, researchers in the lab of David Largaespada, Ph.D., ...
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
(Date:5/19/2013)... study reports that white men and women of European ... valgus) and lesser toe deformities, including hammer or claw ... estimate the heritability of foot disorders in humansappear in ... by Wiley on behalf of the American College of ... many as 60% of older adults have foot disorders ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2
... pondered the possibility that life exists beyond Earth. The ... water, but "following the water" turns out to be ... satellites that possess liquid water is growing faster than ... Astrobiology Institute teams, Arizona State University researchers intend to ...
... as quickly in sand as a fish moves through water, ... Scincus scincus ) that grows to about 15 cm long ... Near East, is commonly known by the name "sandfish."Although it ... two to teach materials-handling and process-technology specialists,as it spends most ...
... BERKELEY, CA Repairing breaks in the two strands of ... humans and other organisms, a molecular machine called the MRN ... then launching the error-free method of DNA repair called homologous ... 3, 2008 issue of the journal Cell , John ...
Cached Biology News:NASA picks ASU research team to guide study of search for life 2NASA picks ASU research team to guide study of search for life 3So-called 'sandfish' could help materials handling and process technology specialists 2So-called 'sandfish' could help materials handling and process technology specialists 3The structure of the Mre11 protein bound to DNA 2The structure of the Mre11 protein bound to DNA 3The structure of the Mre11 protein bound to DNA 4The structure of the Mre11 protein bound to DNA 5The structure of the Mre11 protein bound to DNA 6
... The Flat Block Moto Alpha unit with motorized ... flat surface that is useful for microarrays and ... customized sample blocks. The sealing force of the ... actively measured to give repeatable results. This interchangeable ...
... Anti-Krueppel-like factor 15 (KLF15) KLF15 ... is found abundantly expressed in the liver, ... #: NP_054798 Specificity: Polyclonal antibody produced ... corresponding to a region of human KLF15 ...
... Affi-Prep protein A media yield highly ... prior to analysis of other immunoglobulin ... antigen purification. Protein A binds to ... IgG from mammalian species. This ready-to-use, ...
... is a new tuning and calibration standard ... spectrometry. Accumix is a lyophilized 7-peptide ... for both tuning and calibration of ion ... Fourier transform mass spectrometers. Direct infusion ...
Biology Products: